Gain expert insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown Univeristy Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Start the activity now!
This comprehensive activity presented by faculty experts Aparna Parikh, MD, MS, Harvard Medical School, and Theresa Gillespie, PhD, MA, RN, FAAN, Emory University School of Medicine, will focus on practice guidelines, emerging data on treatment combinations, and strategies to improve quality of life for patients with BRAF V600–mutant metastatic CRC. Start the activity now!
Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity now!
Learn more about emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events in patients with advanced MCC in this activity presented by Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAO. Start now to earn CME/NCPD!
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Start the activity now.
Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now!
Learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Start the activity now!
Gain expert insight and strategies for the management of differentiated and anaplastic thyroid cancer, including emerging data on immunotherapies and strategies to manage adverse events. This activity is presented by leading experts, Jochen Lorch, MD, MSc, Director of the Thyroid Cancer Center, Dana-Farber Cancer Institute, and Carolyn Grande, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center. Start now!
Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now!
Discover new and emerging treatment strategies for advanced classical Hodgkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now!
Anne Chiang, MD, PhD, Yale School of Medicine, a leading expert on small cell lung cancer, for an in-depth presentation on patient outcomes in extensive-small cell lung cancer. Dr. Chiang will present evidence-based advice regarding emerging therapies, strategies for targeted treatments and immunotherapy, optimization of individual patient treatment plans, managing adverse events, and much more! Start the activity now!
Learn new advances in the treatment of relapsed or refractory immune thrombocytopenia, including treatment differentiation, efficacy and safety strategies, and much more. This activity features perspectives from two noted experts in the field, Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse, John Theurer Cancer Center, Hackensack Meridian Health.
This in-depth discussion, presented by Lipika Goyle, MD, Massachusetts General Hospital, will feature expert insights on emerging therapeutic treatments, recent discoveries on novel therapies, managing strategies for monitoring and managing adverse events, and much more! Start the activity now!
Discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This activity features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center. Start now!
In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now!
In the first part of this two-part series, Corey S. Cutler, MD, MPH, FRCPC, shares insights on criteria to appropriately diagnose, grade, and stage graft-versus-host disease (GVHD). Complete part two to hear Dr. Cutler discuss prophylactic strategies for patients undergoing a transplant at high risk for GVHD, emerging data and guideline recommendations in individualized treatment plans for patients with acute and chronic GVHD, and case studies on GVHD. Start now!